ArticleBreast cancer research and treatment2026
A breast clinical scoring system to identify women with Idiopathic granulomatous Mastitis.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIdiopathic granulomatous mastitis (IGM) is a benign inflammatory breast condition that can resemble mastitis or malignancy clinically and radiographically. We aimed to develop a quantitative scoring system, based off the Komen Inflammatory Breast Cancer (IBC) scoring system [1], evaluating clinical and radiologic features to distinguish IGM from benign and malignant breast conditions.
methodsWe conducted a retrospective chart review of biopsy-proven IGM patients diagnosed from 2014 to 2025 via institutional electronic medical records. Clinical symptom onset, features, and diagnostic imaging were analyzed. A continuous scoring scale (1-50) was created, encompassing three categories: symptom onset, clinical features, and radiographic findings. Scores of IGM patients were compared with those of patients diagnosed with IBC, mastitis (lactational and non-lactational), and locally advanced breast cancer (LABC). Welch's two-sample t-test assessed statistical differences, and Youden index identified the optimal score threshold for predicting IGM.
resultsAmong 148 IGM patients, predominantly Hispanic (56.8%) and Asian (26.7%), the mean age was 37.2 years, older than mastitis patients and younger than IBC patients. Key clinical features included pain or painful breast mass (100%), fistula or draining wound (77.7%), erythema (94.6%), and phlegmon (87.8%). Imaging revealed mass with collection in 84.6% and multiple masses/collections in 38.9%. The mean IGM score (35.5) was significantly higher than scores for IBC, mastitis, and LABC groups (14.4, 18, and 15.2, respectively; p ≤ 0.05). A score ≥ 24.5 predicted IGM with 93% sensitivity and 95% specificity.
conclusionsThis novel scoring system provides an objective framework to differentiate IGM from similar breast conditions, facilitating early diagnosis and guiding appropriate management. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
42902029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.